10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Rating of “Hold” by Analysts

10x Genomics, Inc. (NASDAQ:TXG) has received an average rating of “Hold” from the seventeen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.57.

Several brokerages recently weighed in on TXG. Leerink Partnrs downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Barclays cut their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Citigroup decreased their price objective on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a research report on Wednesday, February 19th.

Insider Buying and Selling

In other 10x Genomics news, Director Alan Mateo bought 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were acquired at an average price of $11.14 per share, with a total value of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares of the company’s stock, valued at $687,237.74. The trade was a 184.41 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.03% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TXG. Signaturefd LLC boosted its position in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after acquiring an additional 1,452 shares during the period. GF Fund Management CO. LTD. bought a new stake in 10x Genomics during the fourth quarter valued at $32,000. Capital Performance Advisors LLP purchased a new position in 10x Genomics during the third quarter worth about $35,000. Blue Trust Inc. increased its position in shares of 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Sound Income Strategies LLC raised its stake in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

10x Genomics Trading Down 1.6 %

NASDAQ TXG opened at $11.11 on Wednesday. The firm’s 50 day simple moving average is $14.16 and its 200 day simple moving average is $16.95. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -7.31 and a beta of 1.85. 10x Genomics has a 1 year low of $10.63 and a 1 year high of $48.42.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, equities research analysts forecast that 10x Genomics will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.